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Background: Less than 50 patients with FPD/AML (OMIM 601309) have been reported as of today and there may
an underestimation. The purpose of this study was to describe the natural history, the haematological features and
the genotype-phenotype correlations of this entity in order to, first, screen it better and earlier, before leukaemia
occurrence and secondly to optimize appropriate monitoring and treatment, in particular when familial stem cell
transplantation is considered.
Methods: We have investigated 41 carriers of RUNX1 alteration belonging to nine unrelated French families with
FPD/AML and two syndromic patients, registered in the French network on rare platelet disorders from 2005 to
2015.
Results: Five missense, one non-sense, three frameshift mutations and two large deletions involving several genes
including RUNX1 were evidenced. The history of familial leukaemia was suggestive of FPD/AML in seven pedigrees,
whereas an autosomal dominant pattern of lifelong thrombocytopenia was the clinical presentation of two.
Additional syndromic features characterized two large sporadic deletions. Bleeding tendency was mild and
thrombocytopenia moderate (>50 x109/L), with normal platelet volume. A functional platelet defect consistent with
a δ-granule release defect was found in ten patients regardless of the type of RUNX1 alteration. The incidence of
haematological malignancies was higher when the mutated RUNX1 allele was likely to cause a dominant negative
effect (19/34) in comparison with loss of function alleles (3/9). A normal platelet count does not rule out the
diagnosis of FPD/AML, since the platelet count was found normal for three mutated subjects, a feature that has a
direct impact in the search for a related donor in case of allogeneic haematopoietic stem cell transplantation.
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Conclusions: Platelet dysfunction suggestive of defective δ-granule release could be of values for the diagnosis of
FPD/AML particularly when the clinical presentation is an autosomal dominant thrombocytopenia with normal
platelet size in the absence of familial malignancies. The genotype-phenotype correlations might be helpful in
genetic counselling and appropriate optimal therapeutic management.
Keywords: Thrombocytopenia, Familial platelet disorder with predisposition to acute myeloid leukaemia, RUNX1,
Leukaemia, δ-granule release defectBackground
Four syndromes due to inheritance of a single abnormal
copy of a gene coding for a transcription factor that is
critical for haematopoiesis have been identified as pre-
disposition syndromes for familial myelodysplastic syn-
drome (MDS) or acute leukaemia (AL). The involved
genes are RUNX1 (familial platelet disorder with propen-
sity to develop acute myeloid leukaemia, FPD/AML,
OMIM 601399) [1], CEBPA [2] and more recently
GATA-2 [3] and ETV6 [4]. The clinical usefulness of
identifying these syndromes, which may be more com-
mon than previously thought, is obvious. They raise
questions about their clinical detection and manage-
ment. Heterozygous germline nonsense or missense mu-
tations in RUNX1 were identified as the causative
abnormality in FPD/AML, the first described of the four
[1]. Less than 50 mutation-positive pedigrees have been
reported in the literature [5]. Whole or partial hemizy-
gous RUNX1 deletions can also occur [6]. Recently,
some intragenic deletions and duplications undetectable
by sequencing were reported [7]. Platelet abnormalities
participate to the definition of FPD/AML [8, 9]. Time
elapsed between the detection of thrombocytopenia and
the diagnosis of FPD/AML can amount to several years:
thus FPD/AML diagnosis remains a challenge. This is of
utmost importance when an intra-familiar donor is con-
sidered for hematopoietic stem cell transplantation
(HSCT) [10].
By retrospectively collecting and analysing the data of
41 affected subjects from nine unrelated French families
and two syndromic patients, we mainly aimed at im-
proving the characterization of the clinical and labora-
tory phenotype of FPD/AML in order to identify some
clues, readily obtained in clinical practice, for appropri-
ate recognition of this syndrome. This group of patients
with germline RUNX1 mutations or deletions is the lar-
gest collected up to now.Methods
Organization of the French registry and data monitoring
All patients included in this study were registered in the
French network on rare platelet disorders: ‘Centre de
Reference des Pathologies Plaquettaires’, founded in 2004
and based on prospective enrolment. All types ofinherited platelet disorders have been included. The
registry was started in 2008. Five Reference Centres and
two Competence Centres of inherited platelet disorders
have participated in the registry. Clinical and laboratory
data monitoring was based on the retrospective review
of medical records by each physician in charge of the pa-
tient or by a clinical research associate. The patient or
his- her legal guardians provided written informed con-
sent before being included in the registry. Informed con-
sent were obtained before peripheral blood and bone
marrow sampling from all the studied members of the
families or the parents of the children in accordance
with the Declaration of Helsinki. Some patients were
previously and partially reported but without detailed in-
formation neither on platelet and megakaryocyte pheno-
types nor on clinical follow up: pedigrees B and F [11];
pedigrees C and I [12]; pedigree H and patient J [13].
The collection of these data reflects the collaboration
of French centres in the frame of a network on platelet
disorders.
Clinical investigation
The FPD/AML manifestations mainly consist in haem-
atological features which were collected in this study.
Bleeding symptoms were evaluated according to the
International Society of Thrombosis and Haemostasis
(ISTH)- bleeding assessment tool (BAT) [14]. The age
and the mode of discovery of the thrombocytopenia, the
age at which leukaemia (AL) arose and its type (accord-
ing to OMS 2008 classification), the treatment by famil-
ial or unrelated donor allogeneic HSCT and the lapse of
time between thrombocytopenia detection and FPD/
AML diagnosis were collected. Others features were re-
ported for syndromic forms.
Platelet and bone marrow investigations
Platelet count and mean platelet volume (MPV) were
measured with ethyldiaminetetraacetic acid (EDTA)
anticoagulated peripheral blood in each centre with its
haematological analyser. Platelet volume and size were
analysed according to the French Platelet Reference
Centre recommendations, taking into account the differ-
ences between cell counters [15]. Platelet functional in-
vestigations were performed for eight pedigrees (A to I
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of aspirin and non-steroidal anti-inflammatory agents.
Peripheral blood was anticoagulated with 3.8 % sodium
citrate. Platelet aggregation was evaluated by light trans-
mission aggregometry (LTA) with platelet rich plasma
(PRP) in response to several agonists at different concentra-
tions depending on the laboratory: arachidonic acid (AA)
(1.36 mM), adenosine diphosphate (ADP) (2; 5; 10 μM),
collagen (2; 10 μg/mL), epinephrine (1.2; 2.4; 5.0; 10.0;
50.0 μM) and agglutination in the presence of ristocetin
(0.5; 0.8; 1.5 mg/mL). Dense (δ)-granules and release of
their content were investigated by various means: ATP re-
lease during platelet aggregation in a lumiaggregometer
(Chrono-Log) with the luciferin-luciferase reagent [16]; flow
cytometry assay using mepacrine (a compound selectively
taken up into δ-granules) as previously described [17] in
combination with CD63 (granulophysin, a membrane
marker of δ-granules) expression after stimulation [18];
serotonin content; or electron microscopy (EM). Flow cyto-
metric quantitation of glycoproteins GPIbα (CD42b), GPIIb
(CD41a) and GMP140 (CD62P) on the platelet surface with
or without activation with thrombin receptor activation
(TRAP) was performed with the PLT Gp/Receptors kit
(Biocytex, Marseille, France).
Bone marrow aspirate smears, when performed, were
stained with May-Grünwald-Giemsa.
RUNX1 analysis
RUNX1 analyses were performed in haematological and
genetic laboratories (Lille, Marseille, Nancy, Paris-
Trousseau).
Mutation screening
Total genomic DNA was extracted from peripheral
blood using the Nucleon™ BACC genomic DNA extrac-
tion kit (GE Healthcare). The coding region between
exons 1 to 8 of RUNX1 was amplified by PCR and dir-
ectly sequenced as described [11]. Sequence variants were
numbered starting from the first base of the ATG codon,
numbering based on reference sequence NM_1754.4 (this
splicing variant represents the c isoform). Variant calling
was performed with the Alamut 2.3.1 software (Interactive
Biosoftware), in accordance with the Human Genome
Variation Society nomenclature.
Comparative genomic hybridization (CGH) array
Deletions in the 21q22 region were identified by CGH-
array analysis with the Agilent kit 244A (Agilent Tech-
nologies, Santa Clara, CA) or the GenoSensor array (Vysis
Inc, Abbot Laboratories SA, Downers Grove, IL, USA) in
pedigrees G and H respectively. CGH-array analysis was
performed as previously described [13]. The array was
analysed with an Agilent scanner and the FeatureExtraction software (v10.7.3.1). A graphical overview was
obtained using CGH analytics software (v4.0.76).
Real-time quantitative PCR
Validation of copy number variations (CNVs) identified
with CGH-array was performed by real-time quantitative
PCR on genomic DNA, using the ABI PRISM 7500 Se-
quence Detection System (Applied Biosystems, Foster
City, CA) [13]. For each new CNV, we tested three pri-
mer sets located in the chromosomal region of interest
to establish the de novo inherited feature of the chromo-
somal imbalance.
Literature review
In order to identify all publications related to FPD/AML
syndrome, we screened PubMed, with the key words:
thrombocytopenia, leukaemia and RUNX1. We then
checked the bibliography of each article in order to iden-
tify additional references and to avoid duplicates.
Results
Clinical and haematological data
The French FPD/AML cohort consists of nine pedigrees
(A to I) and two syndromic patients (J and K) with
germline RUNX1 alterations identified in eight hospitals
(La Timone and Paoli-Calmettes in Marseille; Nancy; La
Pitié-Salpetrière, Saint-Louis and Trousseau in Paris;
Reims, Rennes).
Only family pedigrees are shown in Fig. 1 as for patients
J and K the genetic defect consists of a de novo, sporadic,
large deletion. The natural history and the main haemato-
logical features are reported below and are summarized in
Table 1. The first family member mentioned below is the
proband of each pedigree (Table 1). The age at
thrombocytopenia diagnosis varied from two to 67 years.
When assessed, the ISTH-BAT was found to be between
0 and 4 in all patients but one (E/III:5), who presented
with menorrhagia and had a bleeding score of 8.
Pedigree A Thrombocytopenia was detected in A/II:2
during her first pregnancy at the age of 26. This
thrombocytopenia was also present in her three year old
daughter (A/III:2), her brother (A/II:1) and father (A/I:2)
who first developed acute myeloid leukaemia (AML) and
deceased of an unclassified AML(UC-AML) six years
after HSCT at the age of 39.
Pedigree B Thrombocytopenia had not been diagnosed
in B/III:6 before the occurrence of AML-M0 at the age
of 41. Thrombocytopenia was then evidenced in her
father (B/II:2), brothers (B/III:2; B/III:4), sister (B/III:8)
and nephew (B/IV:3). Five members were affected by
AML: B/II:1 (UC-AML); B/III:2 (AML-M5); B/III:4
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Fig. 1 Description of the nine pedigrees with FPD/AML. : Healthy relatives. : Mutated patient without thrombocytopenia. :
Mutated patient with thrombocytopenia. : Patient diagnosed with malignancy. In each family a black arrow designs the proband
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LTA ATP secretion Platelet dense content Bone marrow
megacaryopoïesis
A/I:2 M NP ND Mild thrombocytopenia NP NP NP NP AML-M0 and UC-AML
33 and 39
39 Death





F 1 ? 70 Normal
pattern
NP NP NP No hematological
malignancy
- Alive
A/III:2 F 1 ? 82 NP NP NP NP NP - Alive
B/II:1 F NP ND Mild thrombocytopenia NP NP NP NP UC-AML - Death
B/II:2 M ND Mild thrombocytopenia NP NP NP NP No hematological
malignancy
- Death
B/III:2 M NP 25 Mild thrombocytopenia NP NP NP NP AML-M5
25
<1 year Death





F NP 41 Mild thrombocytopenia NP NP NP NP AML-M0
42
<1 year Death
B/III:8 F NP ND Mild thrombocytopenia NP NP NP NP No hematological
malignancy
- Alive
B/IV:2 M NP 6 Mild thrombocytopenia NP NP NP NP AML-M4
6
<1 year Death
B/IV:3 M NP ND Mild thrombocytopenia NP NP NP NP No hematological
malignancy
- Alive
C/I:1 F NP 46 84 Normal
pattern
NP Mepacrine and CD63
decreased






M 1 25 119 Normal
pattern
NP Mepacrine decreaed Dysmegakaryopoiesis T-ALL and AML-M1
41 and 43
16 years Death
C/II:2 F 1 18 134 NP NP Mepacrine decreaed Dysmegakaryopoiesis No hematological
malignancy
.- Alive
C/II:3 M NP ND 50 NP NP NP ND AML-M1
15
ND Death
D/I:2 M NP ND ND NP NP NP NP UC- AML
60
ND Death
D/II:1 M 0 NA Normal platelet count NP NP NP NP No hematological
malignancy
- Alive

















Table 1 Summary of the haematological features of the cohort of 43 patients with FPD/AML syndrome associated with RUNX1 mutations (Continued)
D/II:6 M 0 47 90–120 δ-SPD
pattern
NP NP NP AML-M4
51
4 years Alive in CR
D/III:8
proband
M 2 8 90–120 δ-SPD
pattern
NP NP NP T-ALL
28
20 years Alive in CR
E/II.2 M NP ‘Since childhood’ Mild thrombocytopenia NP NP NP NP AML ND Death
E/II:3
proband
M NP ‘Since childhood’ 122 δ-SPD
pattern
NP Mepacrine and CD63
decreased
Dysmegakaryopoiesis MDS - Death
(buccal
neoplasia)
E/II/5 M 4 Since childhood 125 NP NP NP NP No haematological
malignncy
ND Alive
E/II:7 M 3 ‘Since childhood’ 112 δ-SPD
pattern





E/III:4 F 2 ‘Since childhood’ 120 NP NP NP NP No hematological
malignancy
- Alive
E/III:5 F 8 ‘Since childhood’ 145 δ-SPD
pattern





E/III:9 F 3 ‘Since childhood’ 118 δ-SPD
pattern





E/III:10 M 3 ‘Since the birth’ 126 δ-SPD
pattern





F/I:1 F NP ‘Since childhood’ Mild thrombocytopenia NP NP NP NP CLL - Alive
F/II:6
proband
F 3 ‘Since childhood’ 90–120 NP NP NP NP AML-M5
55
55 Alive
F/III:1 F 3 ‘Since childhood’ 120–150 δ-SPD
pattern
NP NP NP No hematological
malignancy
- Alive
F/III:2 F 3 ‘Since childhood’ Mild thrombocytopenia NP NP NP NP T-ALL and AML-M0
18 and 23
18 Death
G/I:2 M 0 ‘Since childhood’ 70 δ-SPD
pattern








M 0 12 79–88 δ-SPD
pattern
NP Normal NP No hematological
malignancy
- Alive
H/II:2 F 1 30 120–150 δ-SPD
pattern







M 2 2 60–90 δ-SPD
pattern





I/I:2 M 0 67 120–180 NP NP NP NP No hematological
malignancy
- Alive
I/II:2 F 1 37 130 δ-SPD
pattern



















Table 1 Summary of the haematological features of the cohort of 43 patients with FPD/AML syndrome associated with RUNX1 mutations (Continued)
I/II:3 F 0 38 140–160 δ-SPD
pattern





M 2 1 90–120 δ-SPD
pattern
Decreased NP Dysmegakaryopoiesis No hematological
malignancy
- Alive




Decreased NP Dysmegackryopoiesis No hematological
malignancy
- Alive
Patient J F 0 10 50–60 δ-SPD
pattern
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when he was 25 years old. Sixteen years later, he was di-
agnosed with T- acute lymphoblastic leukaemia (T-ALL).
He achieved complete remission but developed AML-
M1 and passed away 2 years later. FPD/AML was sus-
pected because his mother (C/I:1) presented with
thrombocytopenia when she was 46 and eventually died
of AML secondary to MDS; his brother (C/II:3) died of
AML-M1 at the age of 15; so far, his sister (C/II:2) has
only thrombocytopenia.
Pedigree D Thrombocytopenia was detected at the age
of 8 as D/III:8 presented with velum petechiae and
bruises and later developed T-ALL at the age of 28. He
successfully underwent HSCT using as a donor his un-
affected sister (D/III:9) who was found to be RUNX1
wild-type. FPD/AML was suspected since his father D/
II:6 presented with AML-M4 and his grandfather D/I:2
presented with an UC-AML when he was 60. Of note,
D/II:1 and D/II:3 also had the mutation but a normal
platelet count.
Pedigree E Thrombocytopenia associated with δ-
granule release defect was diagnosed the same year in
several members as shown in Table 1. E/II:2 presented at
the age of 47 with AML with fatal outcome. E/II:3 pre-
sented at the age of 54 with extensive buccal neoplasia
and worsening thrombocytopenia and succumbed. Bone
marrow analysis had showed marked trilineage dysplasia
with rare, hypolobulated megakaryocytes and strongly
basophilic cytoplasm, leading to the diagnosis of MDS
with trilineage dysplasia. This familial association of δ-
granule release defect with haematological neoplasia led
us to analyse the RUNX1 gene.
Pedigree F F/II:6 had a lifelong history of easy bruis-
ing with thrombocytopenia since childhood. She devel-
oped AML-M5 at the age of 55, underwent HSCT from
her RUNX1 non-mutated sister (F/II:4) and achieved
persistent complete remission. Familial thrombocytopenia
(F/III:1; F/III:2) and propensity to develop malignancies
(F/III:2-T-ALL and AML-M0 at the age of 18 and 23 old
years respectively; F/I:1-CLL) was suspected. Her daugh-
ter (F/III:2) underwent sister (F/III:1) (later found to
be mutated for RUNX1) allogeneic HSCT with fatal
outcome.
Pedigree G Thrombocytopenia was incidentally discov-
ered in G/II:1 at the age of 12 before surgery. His father
(G/I:2) was known to be persistent thrombocytopenic.
Pedigree H H/III:1 was first seen at the age of 2 because
of purpura and found to be thrombocytopenic. No treat-
ment was administered. Four years later, he returned tohospital because of purpura and pancytopenia: an AML-
M2 was then diagnosed. He underwent successful HSCT
from HLA identical unrelated donor and is still in remis-
sion 10 years later. His mother (H/II:2), who had neither
bleeding nor physical abnormality, was found to be
slightly thrombocytopenic.
Pedigree I I/III:2 was first seen at the age of one year
old because of purpura and bruises, leading to the detec-
tion of thrombocytopenia. Several members of the family
were found to be thrombocytopenic: his mother I/II:2,
maternal aunt I/II:3, grandfather I/I:2 but not his cousin
I/III:3. His maternal uncle (I/II:5) had thrombocytopenia
and mild bleeding signs during infancy. I/II:2 developed
AML-M1 at the age of 45 and successfully underwent
HSCT.
Patient J This child was first seen at the age of 10 to ex-
plore speech and developmental delay, hypotonia, asso-
ciated with short stature and microcephaly. Numerous
morphological abnormalities were noticed. Her platelet
count was low but she had no history of bleeding.
Family history was unremarkable.
Patient K The propositus presented with craniofacial
dysmorphism including epicanthus, wide nasal root, low
set ear, ventriculoseptal defect, for which surgical correc-
tion was performed without bleeding, and a severe psy-
chomotor retardation. When she was one year old,
thrombocytopenia was detected and considered to be
immune. At the age of 13, she was hospitalised for pan-
cytopenia leading to the diagnosis of refractory anaemia
with blasts excess type 2. AML appeared seven months
later. She successfully underwent sister allogeneic HSCT
which was followed by AML relapse three years later.
No other family members were found to be affected with
thrombocytopenia or haematological malignancy.
Platelet functional phenotypes
For the patients who developed leukaemia, data were
obtained before its occurrence. MPV and platelet size
were normal for all affected patients.
Platelet functional studies were carried out for 20 pa-
tients from eight unrelated pedigrees (A to I except B)
and for patient J (Table 1). No such studies were per-
formed for subjects belonging to pedigree B and for pa-
tient K, because samples were not available.
LTA was realized in the majority of cases. Second wave
of aggregation in response to ADP was absent (except in
pedigrees A and C), associated or not with a decreased
aggregation in response to AA, epinephrine and colla-
gen. These patterns suggested defective δ-granules re-
lease which was consistent with the findings for 10
patients evaluated with other assays (Table 1): decreased
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duced ATP release; reduced uptake and release of fluor-
escent mepacrine and decreased CD63 membrane
expression after stimulation (Table 1). No defect was de-
tected for the other explored glycoproteins (CD42b,
CD41, CD62P).
Megakaryocyte morphology
Morphological analysis of bone marrow smears showed
marked dysmegakaryopoiesis in four families (C/I:2, C/
II:1, C/II:2, E/II:3, H/III:1, I/III:2 and I/III:3) (Table 1).
This dysmegakaryopoiesis consisted in the presence of
hypolobulated megakaryocytes with high nucleo-
cytoplasmic ratio, immature megakaryocytes with high
nucleo-cytoplasmic ratio, strongly basophilic cytoplasm
and poorly lobulated nuclei in association with
micromegakaryocytes.
RUNX1 analysis
Overall, 43 patients were found to be affected according
to Sanger sequencing or CGH-array data (Fig. 1). The
genetic alterations consisted of five missense mutations
located to the runt homology domain (RHD), one non-
sense and three frameshift mutations (Table 2). The pos-
ition of these mutations in the RUNX1 gene are shown in
Fig. 2. There was no recurrent mutation, each one being
unique to a given family. In addition, we found two
complete deletions of the RUNX1 locus (patients J and K).
The predicted protein changes and their consequences
(dominant negative or haploinsufficiency) are mentioned
in Table 2. The effects of the RUNX1 changes on pre-
mRNA splicing and mRNA translation were not studied
in vivo.
Discussion
The addition of clinical and laboratory data from a large
number of patients and families with FPD/AML is useful
to gain further insight into this syndrome because: i) this
platelet disorder is rare; ii) pedigrees reported up to now
are small and affected members still alive are few. In this
study we report on a national survey in France including
two syndromic patients and nine pedigrees, of which
three have not yet been published at all. Furthermore,
we provide a more complete description of the cases
that had been partially reported in previous studies.
Our survey underlines that to date, FPD/AML remains
first and foremost discovered after the occurrence of a
haematological malignancy in seven pedigrees (A, B, C,
D, E, G, H) (Fig. 1, Table 1). Haematological malignan-
cies included eighteen AML, three MDS, and three T-
ALL. Of note, two individuals first developed T-ALL
followed by AML-M1 (C/II:1) and M0 (F/III:2) and one
suspected patient (A/I:1) developed AML and died of re-
lapse six years after HSCT. The lapse of time to FPD/AML diagnosis varied from several months to 55 years
and most frequently corresponded to the time elapsed
between the diagnosis of thrombocytopenia and the
diagnosis of haematological malignancy. A syndromic
thrombocytopenia associated with mental retardation and/
or cardiac abnormalities was the second clinical phenotype
in two patients. In these two patients (patients J, K) and as
discussed by Van der Crabben et al. [19] the complete dele-
tion of not only RUNX1 but also several nearby genes are
likely to contribute to the syndromic features. An isolated
autosomal dominant (AD) inherited thrombocytopenia
with a lifelong mild bleeding tendency was the third type of
presentation in two pedigrees (F, I).
In this study we confirm that this AD thrombocytopenia
was moderate (>50 x109/L) sometimes near the lower
limit of normal range [7, 8, 20, 21] and that patients with
complete RUNX1 deletion had a lower platelet count than
those with RUNX1 mutation (Table 1) [19, 22]. Spontan-
eous bleeding was most often absent or mild and ISTH
bleeding scores were less than 4 but one patient. These
scores are low and several reasons might explain that. (i)
At the present time we cannot use a specific bleeding as-
sessment for detection of platelet bleeding disorders: those
used, in particular ISTH-BAT derived from the score vali-
dated for detection of von Willebrand disease, are not pre-
dictive of the presence of platelet defects [23]. (ii)
Inherited disorders are commonly associated with a
milder bleeding phenotype that comprises spontaneous
cutaneous bleeding and abnormal bleeding after surgery,
trauma and childbirth. All the patients we reported on
and with low bleeding scores have not had surgery: thus
so the score is probably underestimated. We can
stress that mutated women have had bleeding neither
during their pregnancies nor after delivery. (iii) Since
thrombocytopenia is often moderate, sometimes close
to the lower limit of the normal range, even with a δ-
granule secretion defect, the bleeding tendency could be
very mild. Interestingly, within a given family, some pa-
tients with the mutation may have thrombocytopenia and
bleeding, whereas others do not (D/I:1 and D/II:3; I/III:3).
Moreover, for some subjects, platelet count may be nor-
mal and/or thrombocytopenia can appear later (F/II:1; I/
I:2 and I/II:3). Therefore, in the context of unexplained fa-
milial bleeding tendency and/or familial haematological
neoplasia, the screening of mutated patient cannot rely
only on the platelet count as already pointed out in FPD/
AML [24] and in other inherited platelet disorders. An-
other consequence is that the screening for a related
donor for HSCT must be performed only by the analysis
of RUNX1 which should not be restricted to members
with thrombocytopenia. It was suggested that a sex-
chromosome FPD/AML predisposition allele may account
for a male predominance of affected individuals [25]. In
our cohort of 41 mutated subjects, excluding those with
Table 2 Genotypic data and relationship with leukaemia
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NA p.0
Sequence variants were numbered starting from the first base of the ATG codon, numbering based on reference sequence NM_1754.4 containing 9 exons with 8 coding exons
a: The effect of the mutation at the protein level was not tested in vitro as we did not perform any functional analyses. This classification is based on the type and/or position of the mutations affecting the RUNX1
coding region
RHD: runt homology domain; TAD: trans-activation domain; LOH: loss of heterozygosity
b: Theoretical effect at the protein level (the effects of the RUNX1 mutation on pre-mRNA splicing and mRNA translation were not studied). Mutant premature stop codons often trigger nonsense-mediated mRNA


















Fig. 2 Position of the mutations detected in the RUNX1 gene
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males. Thrombocytopenia is secondary to bone marrow
dysmegakaryopoiesis. In the literature, bone marrow in-
vestigation is poorly documented before the occurrence of
myelodysplasia and/or leukaemia. When reported, dysme-
gakaryopoiesis is particularly important [20, 21, 24, 26]
and is in our experience a clue for early diagnosis [27, 28].
The megakaryocytic dysplasia can be considered as pre-
leukaemic abnormalities and reflects the abnormal mega-
karyopoiesis secondary to the germline RUNX1 mutation.
Indeed, Runx 1 is a transcription factor playing a key role
not only in megakaryocyte maturation and differentiation
but also in both ploidization and proplatelet formation
[12]. In one patient (D/III:8) the platelet life span was nor-
mal, consistent with a defective platelet production (data
not shown).
One important aspect is the assessment of platelet
functions and more specifically dense granules release.
Although different approaches were used among the
centres, a δ-granule deficiency or release defect might be
the most prevalent abnormality (Table 1). This defect
cannot be detected by LTA alone and it is essential to
evaluate platelet δ-granule release in order to ensure ac-
curate diagnosis. More specific assays have been devel-
oped as ATP measurement simultaneously with LTA,
mepacrine uptake and release measurement by cytome-
try, EM. When two of those tests were used, δ-granule
release defect was detected in 10 patients before leukae-
mia. As already noticed [24], some affected family mem-
bers had no bleeding history and platelet function
studies were not always extensively performed (pedigrees
A, B, patient K); so the frequency of the defectivephenotype might be underestimated. Moreover, we
found that the δ-granule release defect can be
present not only in patients with bleeding but also
in patients without bleeding history within the same
family (pedigree I) and also in a carrier with a normal
platelet count (I/III:3). Platelet ultrastructural studies can
be helpful in some cases [29]. In our study, EM has been
utilized only once (pedigree I) and showed a moderate re-
duction of δ-granules. In summary, if the number of pa-
tients having a δ − granule release defect is too low to
define the link between platelet functional phenotype and
mutated patient with accuracy, it nevertheless suggests the
value to systematically analyse δ-granule secretion for the
RUNX1 mutated patients. Our study reflects the difficul-
ties to use a same methodology in the different centres
and points to the need for expert recommendations to
standardize the available tests and for studies aimed at
evaluating new methodologies as recently suggested [30].
Other numerous platelet abnormalities have been re-
ported in FPD/AML including impaired platelet aggrega-
tion, decreased platelet spreading, decreased activation of
alphaIIb-beta3, reduced protein phosphorylation of my-
osin light chain [31], decreased production of 12- hydro-
xyeicosatetraenoic acid or one specific protein kinase C
isoform (PKC-θ) [9]. It is known that Runx1 regulates the
expression of genes that could be directly or indirectly in-
volved in platelet function [9] and δ − granule defect could
not be the only explanation for the detected platelet
dysfunction.
A major point is the link between mutations and de-
velopment of leukaemia (Table 2). Molecular investiga-
tions revealed 11 deleterious RUNX1 alterations of
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H, I and patient J) [11–13]. In pedigrees A, D, E and J
the missense and frameshift mutations are novel unre-
ported mutations in FPD/AML.
All disease-causing mutations in RUNX1 are private as
no recurrence has been reported so far. RUNX1 muta-
tions are distributed throughout the gene and can be di-
vided into two main categories (Fig. 2; Table 2).
Complete deletions of RUNX1, splice-site mutations but
also nonsense and frameshift mutations in the N-
terminal region result in the absence of DNA-binding
ability and transactivating potential. These mutants are
very likely to be loss-of-function alleles leading to hap-
loinsufficiency at the protein level (Table 2: pedigrees H,
I; patients J and K). In contrast, missense mutations in
the runt homology domain, frameshift and nonsense
mutants in the C-terminal region, in-frame mutations
may lead to Runx1 proteins with dominant-negative ef-
fects (Fig. 2; Table 2: pedigrees A, B, C, D, E, F, G).
Few data are available concerning genotype-phenotype
correlations in FPD/AML families. Michaud et al. [32]
proposed that mutations with dominant-negative effect
are associated with higher propensity to develop leukae-
mia. We found indeed a higher incidence of MDS/AL in
the seven pedigrees with dominant-negative mutations
(19 MDS/LA among 34 mutated patients) in comparison
with the two pedigrees and the two patients with muta-
tions acting via loss of function (three MDS/LA in nine
mutated patients) (Table 2). For six of the patients who
developed AML in pedigree B: B/III.4; B/III:6, pedigree
D: D/II:6, pedigree F: F/III:2 and III:6, pedigree H: H/
III.1, pedigree I: I/II:2 a second alteration of RUNX1 has
been evidenced as previously reported (Table 2) [11, 33].
These alterations are a new mutation on the second
non-mutated RUNX1 allele, a loss of heterozygosity, a
duplication of the mutated allele. By contrast in two of
the patients (C/II:1; F/III:2) who developed T-ALL [33]
these biallelic alterations of RUNX1 were not present.
The secondary genetic events that contribute to
leukemic transformation remain largely unknown. Re-
cently, Yoshimi et al. reported that somatic mutation in
CDC25C is a recurrent event in the early phase of
leukemic progression of FPD/AML, which induces pre-
mature mitosis and genetic instability in haematopoietic
cells carrying germline RUNX1 mutation [34]. Adequate
medical follow-up of RUNX1 mutated patients with only
an autosomal thrombocytopenia remains a matter of
debate.
The last point of discussion is the differential diagno-
sis. Two other inherited platelet disorders predisposing
to leukaemia belong to the same sub group as FPD/
AML ie the subgroup of AD thrombocytopenias with
normal platelet volume and dysmegakaryopoiesis. These
disorders are linked to mutations in the 5′UTR part ofthe gene coding for ankyrin repeat domain 26
(ANKRD26) (THC2, OMIM 188000) [35, 36] or ETV6
gene [4]. We have recently described that in patients’
platelets with FPD/AML there is a persistence of the
MYH10 protein (pedigree C patients C/II:1, C/II:2; pedi-
gree I patients I/II:2, I/III:2; patient J) [37]. The interest
of this detection was underscored by another group [7].
At the present time this detection can be performed only
by western blotting, a method not widely used by all the
laboratories but we think it constitutes a good screening
to perform a more targeted genetic testing of the
patients.
Conclusion
In conclusion, our study reported the largest group of
patients with germline RUNX1 alteration on a nation-
wide basis. Our data clearly emphasize some clinico-
biological associations, especially the possible link be-
tween a defective release of δ-granules and FPD/AML.
This hallmark is of great importance for the genetic
screening of patients presenting with isolated AD inher-
ited thrombocytopenia with normal platelet volume and
without familial history of leukaemia or MDS. An im-
proved awareness of this platelet disorder and an earlier
diagnosis are warranted although such a diagnosis raises
many questions about genetic counselling and appropri-
ate therapeutic management.
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